Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fernando Bermejo

Showing results (71-80 of 133) with videos related to

Pageof 14
Sort By:
Biomedicines|May 28, 2022
Evaluation in a Cytokine Storm Model In Vivo of the Safety and Efficacy of Intravenous Administration of PRS CK STORM (Standardized Conditioned Medium Obtained by Coculture of Monocytes and Mesenchymal Stromal Cells)Juan Pedro Lapuente, Gonzalo Gómez, Joaquín Marco-Brualla, et al.
Journal of Crohn'S & Colitis|March 9, 2012
Induction of psoriasis with anti-TNF agents in patients with inflammatory bowel disease: a report of 21 casesIván Guerra, Alicia Algaba, José Lázaro Pérez-Calle, et al.
Digestive Diseases and Sciences|December 21, 2016
Adalimumab Maintenance Treatment in Ulcerative Colitis: Outcomes by Prior Anti-TNF Use and Efficacy of Dose EscalationCarlos Taxonera, Eva Iglesias, Fernando Muñoz, et al.
Gastroenterologia Y Hepatologia|June 26, 2016
IV Spanish Consensus Conference on Helicobacter pylori infection treatmentJavier P Gisbert, Javier Molina-Infante, Javier Amador, et al.
Inflammatory Bowel Diseases|February 2, 2021
Re-induction With Intravenous Ustekinumab in Patients With Crohn's Disease and a Loss of Response to This TherapyFernando Bermejo, Laura Jiménez, Alicia Algaba, et al.
Biomolecules|April 23, 2022
Cytokine Profile and Anti-Inflammatory Activity of a Standardized Conditioned Medium Obtained by Coculture of Monocytes and Mesenchymal Stromal Cells (PRS CK STORM)Juan Pedro Lapuente, Alejandro Blázquez-Martínez, Joaquín Marco-Brualla, et al.
Gastroenterologia Y Hepatologia|July 5, 2011
Adalimumab is effective in long-term real life clinical practice in both luminal and perianal Crohn's disease. The Madrid experienceJosé Ignacio Fortea-Ormaechea, Yago González-Lama, Begoña Casis, et al.
Digestive Diseases and Sciences|June 6, 2015
Infliximab Dose Escalation as an Effective Strategy for Managing Secondary Loss of Response in Ulcerative ColitisCarlos Taxonera, Manuel Barreiro-de Acosta, Marta Calvo, et al.
Pancreatology : Official Journal of the International Association of Pancreatology (IAP) ... [Et Al.]|March 14, 2020
Idiopathic acute pancreatitis in patients with inflammatory bowel disease: A multicenter cohort studyAna Garcia Garcia de Paredes, Enrique Rodriguez de Santiago, Carlos Rodriguez-Escaja, et al.
Journal of Crohn'S & Colitis|January 21, 2016
Outcomes of Medical and Surgical Therapy for Entero-urinary Fistulas in Crohn's DiseaseCarlos Taxonera, Manuel Barreiro-de-Acosta, Guillermo Bastida, et al.
Pageof 14

Showing results (71-80 of 133) with videos related to

Sort By:
Pageof 14
Biomedicines|May 28, 2022
Evaluation in a Cytokine Storm Model In Vivo of the Safety and Efficacy of Intravenous Administration of PRS CK STORM (Standardized Conditioned Medium Obtained by Coculture of Monocytes and Mesenchymal Stromal Cells)Juan Pedro Lapuente, Gonzalo Gómez, Joaquín Marco-Brualla, et al.
Journal of Crohn'S & Colitis|March 9, 2012
Induction of psoriasis with anti-TNF agents in patients with inflammatory bowel disease: a report of 21 casesIván Guerra, Alicia Algaba, José Lázaro Pérez-Calle, et al.
Digestive Diseases and Sciences|December 21, 2016
Adalimumab Maintenance Treatment in Ulcerative Colitis: Outcomes by Prior Anti-TNF Use and Efficacy of Dose EscalationCarlos Taxonera, Eva Iglesias, Fernando Muñoz, et al.
Gastroenterologia Y Hepatologia|June 26, 2016
IV Spanish Consensus Conference on Helicobacter pylori infection treatmentJavier P Gisbert, Javier Molina-Infante, Javier Amador, et al.
Inflammatory Bowel Diseases|February 2, 2021
Re-induction With Intravenous Ustekinumab in Patients With Crohn's Disease and a Loss of Response to This TherapyFernando Bermejo, Laura Jiménez, Alicia Algaba, et al.
Biomolecules|April 23, 2022
Cytokine Profile and Anti-Inflammatory Activity of a Standardized Conditioned Medium Obtained by Coculture of Monocytes and Mesenchymal Stromal Cells (PRS CK STORM)Juan Pedro Lapuente, Alejandro Blázquez-Martínez, Joaquín Marco-Brualla, et al.
Gastroenterologia Y Hepatologia|July 5, 2011
Adalimumab is effective in long-term real life clinical practice in both luminal and perianal Crohn's disease. The Madrid experienceJosé Ignacio Fortea-Ormaechea, Yago González-Lama, Begoña Casis, et al.
Digestive Diseases and Sciences|June 6, 2015
Infliximab Dose Escalation as an Effective Strategy for Managing Secondary Loss of Response in Ulcerative ColitisCarlos Taxonera, Manuel Barreiro-de Acosta, Marta Calvo, et al.
Pancreatology : Official Journal of the International Association of Pancreatology (IAP) ... [Et Al.]|March 14, 2020
Idiopathic acute pancreatitis in patients with inflammatory bowel disease: A multicenter cohort studyAna Garcia Garcia de Paredes, Enrique Rodriguez de Santiago, Carlos Rodriguez-Escaja, et al.
Journal of Crohn'S & Colitis|January 21, 2016
Outcomes of Medical and Surgical Therapy for Entero-urinary Fistulas in Crohn's DiseaseCarlos Taxonera, Manuel Barreiro-de-Acosta, Guillermo Bastida, et al.
Pageof 14